References
- Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia. Neurology56, 1154–1166 (2001).
- •Evidence-based review.
- Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-BEST Study. Int. Geriat. 13,Fhiatry14, 135–146 (1999).
- •Benefit and efficacy in severely demented patients during treatment with memantine.
- Pratt RD, Pedformo CA, The Donepezil 308 VaD Study Group. Cognitive and global benefits of donepezil in vascular dementia: results from Study 308, a 24- week, randomized, double-blind, placebo-controlled trial. Presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, April 3–6 (2002).
- Pratt RD, Pedformo CA, The Donepezil 307 VaD Study Group. Donepezil improves cognition in patients with vascular dementia: results from Study 307, a 24-week, randomized, double-blind, placebo-controlled trial. Presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, Geneva, Switzerland, April 3–6 (2002).
- Erkinjuntti T, Kurz A, Gauthier S et al Efficacy of galantamine in probable vascular dementia and Alzheimer's combined with cerebrovascular disease: a randomized trial. Lancet 359, 1283–1290 (2002).
- McKeith I, Del Ser T, Spano P et al Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study. Lancet356, 2031–2036 (2000).
- Gauthier S. Advances in the pharmacotherapy of Alzheimer's disease. CM4J166, 616–623 (2002).
- Petersen RC, Doody R, Kurz A et al. Current concepts in Mild Cognitive Impairment, Arch. Neural. 58, 1985–1992 (2001).
- Knapp M, Wilkinson D, Wigglesworth R. The economic consequences of Alzheimer's disease in the context of new drug developments. Int. J: Geriat. 13,Fhiatry13, 531–543 (1998).